Cingulate (CINGW) Competitors

$0.02 +0.00 (+5.00%)

As of 10:02 AM Eastern

CINGW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you buy Cingulate stock or one of its competitors? MarketBeat compares Cingulate with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cingulate include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Cingulate compare to Ainos?

Ainos (NASDAQ:AIMDW) and Cingulate (NASDAQ:CINGW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$124.16K	N/A	N/A	N/A	N/A
Cingulate	N/A	N/A	N/A	N/A	N/A

In the previous week, Cingulate had 3 more articles in the media than Ainos. MarketBeat recorded 4 mentions for Cingulate and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Cingulate's score of 0.47 indicating that Ainos is being referred to more favorably in the media.

Company	Overall Sentiment
Ainos	Very Positive
Cingulate	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Cingulate	N/A	N/A	N/A

Summary

Ainos beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Cingulate compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Cingulate (NASDAQ:CINGW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$586.32M	N/A	N/A	N/A	N/A
Cingulate	N/A	N/A	N/A	N/A	N/A

In the previous week, Cingulate had 2 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Cingulate and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.44 beat Cingulate's score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Company	Overall Sentiment
Alvotech	Positive
Cingulate	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
Cingulate	N/A	N/A	N/A

Summary

Alvotech beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Cingulate compare to Aravive?

Aravive (NASDAQ:ARAV) and Cingulate (NASDAQ:CINGW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Cingulate	N/A	N/A	N/A	N/A	N/A

In the previous week, Cingulate had 4 more articles in the media than Aravive. MarketBeat recorded 4 mentions for Cingulate and 0 mentions for Aravive. Cingulate's average media sentiment score of 0.47 beat Aravive's score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Cingulate	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Cingulate	N/A	N/A	N/A

Summary

Aravive and Cingulate tied by winning 2 of the 4 factors compared between the two stocks.

How does Cingulate compare to Atlantic Coastal Acquisition Corp. II?

Cingulate (NASDAQ:CINGW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

In the previous week, Cingulate had 4 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 4 mentions for Cingulate and 0 mentions for Atlantic Coastal Acquisition Corp. II. Cingulate's average media sentiment score of 0.47 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

Summary

Cingulate beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Cingulate compare to Avidity Biosciences?

Cingulate (NASDAQ:CINGW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

In the previous week, Cingulate had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Cingulate and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.94 beat Cingulate's score of 0.47 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Avidity Biosciences	Positive

Cingulate has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Cingulate's return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Cingulate has higher earnings, but lower revenue than Avidity Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	N/A	N/A	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Avidity Biosciences has a consensus price target of $69.42, suggesting a potential upside of 420.01%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Summary

Avidity Biosciences beats Cingulate on 6 of the 10 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CINGW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CINGW vs. The Competition

Export

Metric	Cingulate	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$460.17M	$6.29B	$12.46B
Dividend Yield	N/A	3.86%	2.79%	5.30%
P/E Ratio	N/A	3.78	20.85	25.56
Price / Sales	N/A	7,812.86	543.57	72.25
Price / Cash	N/A	13.13	42.94	55.34
Price / Book	N/A	83.89	9.87	6.72
Net Income	N/A	-$96.07M	$3.55B	$333.62M
7 Day Performance	N/A	0.74%	-0.23%	0.35%
1 Month Performance	N/A	0.80%	1.47%	4.00%
1 Year Performance	N/A	70.32%	41.05%	36.32%

Cingulate Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CINGW Cingulate	N/A	$0.02 +5.0%	N/A	-53.7%	$0.00	N/A	N/A	20	News Coverage Short Interest Increase Gap Down
AIMDW Ainos	N/A	$0.10 +40.1%	N/A	-21.3%	$0.00	$124.16K	N/A	40	Positive News Gap Up
ALVOW Alvotech	N/A	$0.26 +30.0%	N/A	-86.0%	$0.00	$586.32M	N/A	4	Positive News Short Interest Decrease Gap Up
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CINGW) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cingulate (CINGW) Competitors